Grace Therapeutics, Inc.
GRCE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001444192
In the last 90 days, Grace Therapeutics, Inc. insiders filed 5 open-market purchases and 0 sales; 33 institutions reported holding it in 13F filings for Q2 2026, worth $8.74M in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding Grace Therapeutics, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 9 | 10 | +1 |
| Shares | 152.1K | 127.3K | −24.8K (−16.3%) |
| Value | $183.7K | $108.2K | −$75.5K (−41.1%) |
New holders (5)
Institutions that held Grace Therapeutics, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna International Group, LLP | 25,962 | $22.0K | 0.00% |
| Two Sigma Securities, LLC | 25,496 | $22.0K | 0.00% |
| Virtu Financial LLC | 19,715 | $17.0K | 0.00% |
| TD Waterhouse Canada Inc. | 4 | $4 | 0.00% |
| Toronto Dominion Bank | 57 | $0 | 0.00% |
Sold out (4)
Institutions that held Grace Therapeutics, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Bank of America Corp | 56,583 | $69.0K |
| Koshinski Asset Management, Inc. | 2,000 | $2.44K |
| Tower Research Capital LLC (TRC) | 612 | $1.00K |
| UBS Group AG | 1,188 | $1.00K |